Atypical HemolyticUremic Syndrome: A Clinical Review

American Journal of Therapeutics

Volumn 23, Issue 1, 2016, Pages e151-e158

  Nayer, Ali ^a   Asif, Arif ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

atypical hemolyticuremic syndrome; complements; eculizumab; endothelial cells; kidney

Indexed keywords

COMPLEMENT;

CLINICAL FEATURE; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY TRANSPLANTATION; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; ATYPICAL HEMOLYTIC UREMIC SYNDROME; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT SYSTEM PROTEINS; DIAGNOSIS, DIFFERENTIAL; ENDOTHELIAL CELLS; HUMANS; PROGNOSIS;

EID: 84955676758     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31829b59dc     Document Type: Review

References (34)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676-1687.
2. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60.
3. Laurence J. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol. 2012;10:3-9.
4. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8:622-633.
5. Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57.
6. Goldberg RJ, Nakagawa T, Johnson RJ, et al. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis. 2010;56:1168-1174.
7. Churg J, Strauss L. Renal involvement in thrombotic microangiopathies. Semin Nephrol. 1985;5:46-56.
8. Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785-797.
9. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009;9:729-740.
10. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859.
11. Noris M, Brioschi S, Caprioli J, et al; International Registry of Recurrent and Familial HUS/TTP. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet. 2003;362:1542-1547.
12. Bresin E, Rurali E, Caprioli J, et al; European Working Party on Complement Genetics in Renal Diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013;24:475-486.
13. Nakayama T, Sato W, Yoshimura A, et al. Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney. Am J Pathol. 2010;176:2198-2208.
14. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707-716.
15. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136.
16. Suga S, Kim YG, Joly A, et al. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int. 2001;60:1297-1308.
17. Kavanagh D, Richards A, Goodship T, et al. Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost. 2010;36:653-659.
18. Solaris (Eculizumab) [Prescribing Information]. Cheshire, CT: Alexion Pharmaceuticals; 2012.
19. Koh KK, Bui MN, Hathaway L, et al. Mechanism by which quinapril improves vascular function in coronary artery disease. Am J Cardiol. 1999;83:327-331.
20. Koh KK, Quon MJ, Han SH, et al. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol. 2006;108:96-100.
21. Blanco-Colio LM, Tuñón J, Martín-Ventura JL, et al. Antiinflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63:12-23.
22. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMGcoenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131.
23. Yiginer O, Ozcelik F, Inanc T, et al. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol. 2008;97:334-340.
24. Butler R, Morris AD, Belch JJ, et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35:746-751.
25. Bitzan M, Schaefer F, Reymond D. Treatment of typical (enteropathic) hemolytic uremic syndrome. Semin Thromb Hemost. 2010;36:594-610.
26. Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 360:542-544.
27. Tschumi S, GuggerM, Bucher BS, et al. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol. 2011;26:2085-2088.
28. Chatelet V, Fremeaux-Bacchi V, Lobbedez T, et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant. 2009;9:2644-2645.
29. Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V, et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4:1312-1316.
30. Köse O, Zimmerhackl LB, Jungraithmayr T, et al. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost. 2010;36:669-672.
31. Büttner-Mainik A, Parsons J, Jerôme H, et al. Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnol J. 2011;9:373-383.
32. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508-2516.
33. Beckman JA, Goldfine AB, Gordon MB, et al. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation. 2001; 103:1618-1623.
34. Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant. 2008;12:619-629.